Description
suboxone uk
suboxone uk, Suboxone (buprenorphine/naloxone) is a brand-name prescription drug. It’s used to treat dependence on opioid drugs.
Suboxone comes as an oral film that’s placed under your tongue (sublingual) or between your gums and cheek (buccal). The film dissolves in your mouth.
What is Suboxone? Suboxone is an opioid prescription drug used to treat opioid dependence. It can be used as an induction agent to stabilize someone in withdrawal during the medical detoxification process as well as for maintenance treatment to promote recovery from opioid use disorder.
Suboxone contains two drugs in each film: buprenorphine and naloxone. It’s available in four strengths:
- 2 mg buprenorphine / 0.5 mg naloxone
- 4 mg buprenorphine / 1 mg naloxone
- 8 mg buprenorphine / 2 mg naloxone
- 12 mg buprenorphine / 3 mg naloxone
Common side effects of Suboxone include: constipation, diarrhea, headache, and nausea. Buy Suboxone here
- headache.
- opioid withdrawal symptoms, such as body aches, abdominal cramps, and rapid heart rate.
- anxiety.
- insomnia (trouble sleeping)
- sweating.
- depression.
- constipation.
- nausea.
Technically, Suboxone is a narcotic. When taken as prescribed by a medical provider, buprenorphine/naloxone (Suboxone) should not cause euphoria or a high.
Dosing information
Usual Adult Dose for Opiate Dependence – Induction:
INDUCTION: For those Dependent on Heroin or Other Short-acting Opioid Products:
-INITIAL DOSES should begin when objective signs of moderate opioid withdrawal appear and not less than 6 hours after the patient last used opioids to avoid precipitating an opioid withdrawal syndrome:
Suboxone Sublingual Film:
Day 1: up to 8 mg/2 mg sublingually; administer as an initial dose of 2 mg/0.5 mg or 4 mg/1 mg with titration in 2 or 4 mg increments of buprenorphine at approximately 2-hour intervals
Day 2: 16 mg/4 mg sublingually as a single dose
Comments:
-Patients dependent on heroin or other short-acting opioid products may be inducted with combination buprenorphine/naloxone or buprenorphine monotherapy; to avoid precipitating withdrawal during induction, initiation should occur when clear signs of withdrawal are evident, preferably when moderate objective signs of opioid withdrawal appear, and no sooner than 6 hours after last use of heroin or other short-acting opioid.
-Suboxone sublingual tablets are not indicated for induction therapy; Suboxone sublingual film for sublingual or buccal use should only be administered sublingually for induction to minimize exposure to naloxone.
-For patient’s dependent on methadone or long-acting opioid products, buprenorphine monotherapy should be used during the induction phase as naloxone may be absorbed in small amounts and could precipitate or prolong withdrawal during induction.
-Maintenance treatment begins on day 3.
Use: For the treatment of opioid dependence as part of a complete treatment plan to include counseling and psychosocial support.
Usual Adult Dose for Opiate Dependence – Maintenance:
MAINTENANCE Treatment:
-Doses of buprenorphine/naloxone should be adjusted to a level that holds the patient in treatment and suppresses opioid withdrawal signs and symptoms; doses should be titrated to clinical effectiveness as rapidly as possible as gradual titration may lead to higher drop-out rates.
Reviews
There are no reviews yet.